Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes

• Sponsor: Navidea Biopharmaceuticals (Industry)
• Overall Status: Completed
• CT.gov ID: NCT01106040
• Collaborator: (none)
• Enrollment: 163
• Locations: 8
• Arm: 1
• Duration (Months): 10
• Patients Per Site: 20.4
• Patients Per Site Per Month: 2

Study Details

Study Description

Brief Summary

Data from this pivotal clinical trial will be used to support a marketing application (i.e., NDA) of Navidea's Lymphoseek for use in anatomical delineation of lymphoid tissue (nodes) in the lymphatic pathway draining the primary site of a tumor.

Multicenter, open-label, within-patient comparative study of Lymphoseek and vital blue dye in the detection of excised lymph nodes in patients with known melanoma and breast cancer. All patients will receive a single dose of 50 µg Lymphoseek radiolabeled with 0.5 or 2.0 mCi Tc 99m and vital blue dye.

Condition or Disease	Intervention/Treatment	Phase
Breast Cancer; Melanoma	Drug: Lymphoseek	Phase 3

Detailed Description

In patients with primary melanoma and breast cancer, lymph node status is often a strong predictor of outcome and influences the course of treatment a patient may follow after surgery. In an effort to reduce the morbidity and costs of detection of lymph node metastases, surgical oncologists have developed a method by which the sentinel lymph node (SLN; the first node in a draining basin) is identified intraoperatively and removed. This technique, called sentinel node biopsy, has extremely high negative predictive values for melanoma metastases and breast cancer metastases. The two largest trials for melanoma, Morton, et al (2005) and Rossi, et al (2006), reported false negative rates of 6.3% and 14.7%, respectively. Morton, et al (2006), in perhaps the most mature trial reported to date, showed a false negative rate of 3.4%. There is growing evidence that sentinel node biopsy will have a significant impact on the management of melanoma. Sentinel node biopsy also has extremely high negative predictive values for breast cancer metastases; the false-negative rates range from 0% to 9%. There is growing evidence that sentinel node biopsy will have a significant impact on the management of breast cancer. Although the survival and local recurrence studies have yet to be completed, the technique has emerged into common practice.

Intraoperative lymphatic mapping (ILM) with a radiopharmaceutical is a nuclear medicine examination which identifies for the surgeon the first lymph node to receive lymphatic flow from the primary tumor site. This node is removed and analyzed for the presence of malignant cells. By locating the lymph node prior to surgery, a small incision can be used to remove the node and a smaller dissection can be employed. The high negative predictive value of the technique seems to provide an accurate staging procedure and may spare patients who are lymph node negative the morbidity of a complete lymph node dissection. Consequently, staging of melanoma by lymph node mapping and biopsy may be equivalent to regional node dissection without the attendant post surgical morbidity.

An ideal lymph node imaging agent would exhibit rapid clearance from the injection site, rapid uptake and high retention within the first draining lymph node, and low uptake by the remaining lymph nodes. The ideal agent would also have low radiation absorption; high biological safety; convenient, rapid, and stable technetium-99m labeling; and biochemical purity.

Lymphoseek (Technetium Tc 99m diethylenetriaminepentaacetic acid mannosyl dextran, [Tc 99m] DTPA Mannosyl Dextran) is a radiotracer that accumulates in lymphatic tissue by binding to a mannose binding protein that resides on the surface of dendritic cells and macrophages. Lymphoseek is a macromolecule consisting of multiple units of DTPA and mannose, each synthetically attached to a 10 kilodalton dextran backbone. The mannose acts as a substrate for the receptor, and the DTPA serves as a chelating agent for labeling with Tc 99m.

Lymphoseek has a diameter of about 5 nm, which is substantially smaller than current agents used for targeting lymphoid tissue. Lymphoseek's small diameter permits enhanced diffusion into lymph nodes and blood capillaries, resulting in a rapid injection site clearance. Upon entry into the blood, the agent binds to receptors in the liver or is filtered by the kidney and accumulates in the urinary bladder.

Study Design

• Study Type: Interventional
• Actual Enrollment: 163 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Diagnostic
• Official Title: A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping
• Study Start Date: Jun 1, 2010
• Actual Primary Completion Date: Apr 1, 2011
• Actual Study Completion Date: Apr 1, 2011

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Lymphoseek, Lymphatic mapping, Injection	Drug: Lymphoseek; The total volume of Lymphoseek injection will be between 0.1 - 1.0 mL.; Other Names: technetium Tc 99m tilmanocept

Outcome Measures

Primary Outcome Measures

1. Concordance of Blue Dye and Lymphoseek [Surgery after injections of Lymphoseek and blue dye]

   The proportion of lymph nodes detected intraoperatively by blue dye that were also detected by Lymphoseek.

Secondary Outcome Measures

1. Reverse Concordance of Blue Dye and Lymphoseek [Surgery after injections of Lymphoseek and blue dye]

   The proportion of lymph nodes detected intraoperatively by Lymphoseek that were also detected by blue dye.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. The patient has provided written informed consent with HIPAA authorization.

2. The patient is a candidate for surgical intervention, with lymph node mapping being a part of the surgical plan.

3. The patient is at least 18 years of age at the time of consent.

4. The patient has an ECOG performance status of Grade 0 - 2 (see Appendix A).

5. The patient has a clinical negative node status at the time of study entry (i.e. T0-4, N0, M0, see Appendix D and E).

6. If of childbearing potential, the patient has a negative pregnancy test within 72 hours prior to administration of Lymphoseek, has been surgically sterilized, or has been postmenopausal for at least 1 year.

Melanoma Patients

1. The patient has a diagnosis of primary melanoma. Breast Cancer Patients

2. The patient has a diagnosis of primary breast cancer.

3. Patients with pure ductal carcinoma in situ (DCIS) or non-invasive carcinoma if lymph node biopsy is part of the surgical plan.

Exclusion Criteria:

1. The patient is pregnant or lactating.

2. The patient has clinical or radiological evidence of metastatic cancer including palpably abnormal or enlarged lymph nodes (i.e., all patients should be any T,N0,M0, see Appendix D and E).

3. The patient has a known hypersensitivity to Lymphazurin.

4. The patient has participated in another investigational drug study within 30 days of scheduled surgery.

Melanoma Patients

1. The patient has a tumor with a Breslow depth less than 0.75mm.

2. Patient has had preoperative chemotherapy, immunotherapy, or radiation therapy.

3. Patient has been diagnosed with a prior invasive melanoma that would occur on the same body region or potentially draining to the same nodal basin or patients with truncal or extremity primary melanoma who has had a prior breast cancer potentially draining to the same axillary nodal basin.

4. Patient has undergone node basin surgery of any type or radiation to the nodal basin(s) potentially draining the primary melanoma.

5. Patient has undergone a wide excision for their primary melanoma (>1 cm in dimension) or complex reconstruction (rotation, free flap, or skin graft of any type).

Breast Cancer Patients

1. The patient has bilateral primary breast cancers or multiple tumors within their breast.

2. Patient has had prior surgical procedures such as breast implants, reduction mammoplasty, or axillary surgery.

3. Patient is scheduled for bilateral mastectomy unless for cosmetic reasons and the contraindicated breast will not undergo lymph node mapping.

4. Patient has had preoperative radiation therapy to the affected breast or axilla.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University of Alabama, Birmingham	Birmingham	Alabama	United States	35294
2	UCSD Moores Cancer Center	La Jolla	California	United States	92093
3	Califonia Pacific Medical Center	San Francisco	California	United States	94115
4	John Wayne Cancer Institute	Santa Monica	California	United States	90404
5	H. Lee Moffitt Cancer Center	Tampa	Florida	United States	33612
6	University Hospitals Cleveland	Cleveland	Ohio	United States	44106
7	Breast Care Specialists	Columbus	Ohio	United States	43081
8	The Ohio State University	Columbus	Ohio	United States	43210

Sponsors and Collaborators

• Navidea Biopharmaceuticals

Investigators

• Study Director: Simon A Blackburn, Navidea Biopharmaceuticals

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Navidea Biopharmaceuticals
• ClinicalTrials.gov Identifier: NCT01106040
• Other Study ID Numbers: NEO3-09
• First Posted: Apr 19, 2010
• Last Update Posted: Jun 17, 2013
• Last Verified: Jun 1, 2013

• Keywords provided by Navidea Biopharmaceuticals: Lymphoseek; Breast Cancer; Melanoma; Experimental
• Additional relevant MeSH terms: Breast Neoplasms; Melanoma

Study Results

Participant Flow

Arm/Group Title	Lymphoseek, Lymphatic Mapping, Injection
Arm/Group Description	Melanoma and breast cancer patients to receive a single dose of 50 µg Lymphoseek radiolabeled with 0.5 or 2.0 mCi Tc 99m and blue dye for lymphatic mapping and surgical resection of lymph nodes.
Period Title: Overall Study
STARTED	163
COMPLETED	152
NOT COMPLETED	11

Baseline Characteristics

Arm/Group Title	Lymphoseek
Arm/Group Description	Enrolled patients who were administered any injection of Lymphoseek.
Overall Participants	153
Age (Count of Participants)
<=18 years	0 0%
Between 18 and 65 years	101 66%
>=65 years	52 34%
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	59.3 (12.4)
Sex: Female, Male (Count of Participants)
Female	104 68%
Male	49 32%
Region of Enrollment (participants) [Number]
United States	153 100%

Outcome Measures

1. Primary Outcome

Title	Concordance of Blue Dye and Lymphoseek
Description	The proportion of lymph nodes detected intraoperatively by blue dye that were also detected by Lymphoseek.
Time Frame	Surgery after injections of Lymphoseek and blue dye

Outcome Measure Data

Analysis Population Description

All enrolled patients who were injected with both Lymphoseek and blue dye, who underwent surgery and had at least one lymph node stained intraoperatively by blue dye, and for whom the tissue type (lymphatic/non-lymphatic) and pathology status (presence/absence of tumor cells) was confirmed.

Arm/Group Title	Intent-To-Treat
Arm/Group Description	Participants received a single dose of 50 μg Lymphoseek radiolabeled with 0.5 or 2.0 mCi Tc 99m and blue dye for lymphatic mapping and surgical resection of lymph nodes.
Measure Participants	133
Measure Lymph Nodes	229
Number (95% Confidence Interval) [Proportion of Lymph Nodes]	1.0000

2. Secondary Outcome

Title	Reverse Concordance of Blue Dye and Lymphoseek
Description	The proportion of lymph nodes detected intraoperatively by Lymphoseek that were also detected by blue dye.
Time Frame	Surgery after injections of Lymphoseek and blue dye

Outcome Measure Data

Analysis Population Description

All enrolled patients who were injected with both Lymphoseek and blue dye, who underwent surgery and had at least one lymph node detected by Lymphoseek (at ≥ 3σ count) in vivo, and for whom the tissue type (lymphatic/non-lymphatic) and pathology status (presence/absence of tumor cells) was confirmed.

Arm/Group Title	Reverse Intent-To-Treat
Arm/Group Description	Participants received a single dose of 50 μg Lymphoseek radiolabeled with 0.5 or 2.0 mCi Tc 99m and blue dye for lymphatic mapping and surgical resection of lymph nodes.
Measure Participants	152
Measure Lymph Nodes	378
Number (95% Confidence Interval) [Proportion of Lymph Nodes]	0.6058

Adverse Events

Arm/Group Title	Lymphoseek
Arm/Group Description	Enrolled patients who were administered any injection of Lymphoseek.
All Cause Mortality
	Lymphoseek
	Affected / at Risk (%)	# Events
Total	/ (NaN)
Serious Adverse Events
	Lymphoseek
	Affected / at Risk (%)	# Events
Total	8/153 (5.2%)
Cardiac disorders
Bradycardia	1/153 (0.7%)	1
Tachycardia	1/153 (0.7%)	1
Infections and infestations
Cellulitis	2/153 (1.3%)	2
Herpes Zoster Ophthalmic	1/153 (0.7%)	1
Injury, poisoning and procedural complications
Seroma	1/153 (0.7%)	1
Nervous system disorders
Syncope	1/153 (0.7%)	1
Respiratory, thoracic and mediastinal disorders
Asthma	1/153 (0.7%)	1
Other (Not Including Serious) Adverse Events
	Lymphoseek
	Affected / at Risk (%)	# Events
Total	0/153 (0%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

The PI shall not submit a publication to journals or professional societies without the prior written approval of the Sponsor.